<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530620</url>
  </required_header>
  <id_info>
    <org_study_id>8405010</org_study_id>
    <nct_id>NCT01530620</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity</brief_title>
  <official_title>Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>APOGEPHA Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>APOGEPHA Arzneimittel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to compare efficacy and safety of propiverine
      hydrochloride extended and immediate release formulations in patients suffering from
      neurogenic detrusor overactivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reflex volume (cystometry)</measure>
    <time_frame>three weeks</time_frame>
    <description>Change in reflex volume compared to baseline and compared between the two treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leak point pressure</measure>
    <time_frame>three weeks</time_frame>
    <description>Change in LPP compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leak point volume</measure>
    <time_frame>three weeks</time_frame>
    <description>Change in LPV compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum detrusor pressure</measure>
    <time_frame>three weeks</time_frame>
    <description>Change in maximum p det compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum cystometric capacity</measure>
    <time_frame>three weeks</time_frame>
    <description>Change in maximum cystometric capacity compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder compliance</measure>
    <time_frame>three weeks</time_frame>
    <description>Change in compliance compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of incontinence episodes</measure>
    <time_frame>three weeks</time_frame>
    <description>Change of incontinence episodes compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State of Well-Being Questionnaire</measure>
    <time_frame>three weeks</time_frame>
    <description>Change of well-beeing compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void residual volume</measure>
    <time_frame>three weeks</time_frame>
    <description>Change in PVR compared to baseline and compared between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>three weeks</time_frame>
    <description>occurrences and intensity of adverse events or withdrawals over the whole treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Neurogenic Urinary Bladder Disorder</condition>
  <condition>Urinary Bladder, Neurogenic</condition>
  <condition>Bladder Disorder, Neurogenic</condition>
  <condition>Urinary Bladder Disorder, Neurogenic</condition>
  <condition>Neurogenic Bladder Disorder</condition>
  <condition>Urinary Bladder Neurogenic Dysfunction</condition>
  <condition>Urologic Diseases</condition>
  <condition>Overactive Detrusor Function</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Propiverine hydrochloride ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propiverine hydrochloride IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propiverine hydrochloride ER (extended release)</intervention_name>
    <description>45 mg capsule (1x1/d)</description>
    <arm_group_label>Propiverine hydrochloride ER</arm_group_label>
    <other_name>Mictonorm UNO 45</other_name>
    <other_name>Detrunorm XL 45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propiverine hydrochloride IR (immediate release)</intervention_name>
    <description>15 mg tablet (3x1/d)</description>
    <arm_group_label>Propiverine hydrochloride IR</arm_group_label>
    <other_name>Mictonorm</other_name>
    <other_name>Detrunorm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Caucasian patients aged ≥18 and ≤70 years

          -  Voluntarily signed informed consent

          -  Neurogenic detrusor overactivity with occurrence of reflex detrusor contractions

          -  Reflex volume of ≤250 mL

          -  Intact reflex arcs in the area of segments S2-S4

        Exclusion Criteria:

          -  Patients suffering from multiple sclerosis under unstable conditions

          -  Augmented reflex bladder

          -  Patients with increased residual urine (≥20 % of the maximum bladder capacity), in
             whom catheterization is not possible

          -  Acute urinary tract infection

          -  Electrostimulation therapy (within 4 weeks propir to Visit 1)

          -  Anomalies of the lower genitourinary tract (e.g. ectopic ureters, fistulas, urethral
             stenosis)

          -  Radiation bladder, interstitial cystitis, bladder calculi, bladder carcinoma

          -  Surgery of the lower genitourinary tract within the last 6 months (e.g. prostatectomy,
             hysterectomy, tumor surgery)

          -  Pre-existing medical contraindications for anticholinergics

          -  Cardiac insufficiency (NYHA stage III/ IV)

          -  Therapy with botulinum toxin within the last 12 months

          -  Evidence of severe renal, hepatic or metabolic disorders

          -  History of drug or alcohol abuse

          -  Concomitant medication known to have a potential to interfere with the trial
             medication

          -  Known hypersensitivity to Propiverine hydrochloride or excipients contained in the
             trial medication, respectively

          -  Pregnant or breast-feeding women, or women of childbearing potential without using any
             reliable contraceptive method

          -  Patients with impaired co-operation or who are unable to understand the nature, scope
             and possible consequences of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hagenow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimuscarinics</keyword>
  <keyword>Neurogenic bladder</keyword>
  <keyword>Propiverine</keyword>
  <keyword>Urodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

